Research To Practice | Oncology Videos

Featuring an interview with Prof Axel Hauschild, including the following topics: Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00) Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23) Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAM...

Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics: Emerging data with targeted agents for metastatic melanoma (0:00) Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13) Comparing targeted agents and immune checkpoint inhibitors (17:34) Current melanoma guidelines and other therapies under investigati...

Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics: Prologue (0:00) First-line treatment (3:38) Bispecific antibodies (34:41) CAR T-cell therapy (48:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics: Biology of RET Genetic Alterations in Cancer (0:00) Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44) Mechanisms of Action of Selective RET Inhibitors (3:58) Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04) Updated Effi...

Featuring an interview with Dr Justin Gainor, including the following topics: Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00) Significance of non-fusion RET abnormalities in NSCLC (3:33) Clinical impact of tumor-agnostic targeted therapy (5:11) Incidence and management of chylothorax in patients undergoing treatment...

Featuring perspectives from Dr Nancy Lin, including the following topics: Introduction: Journal Club with Nancy U Lin, MD (0:00) Case: A woman in her late 60s with ER-positive, HER2-positive breast cancer who has significant neuropathy and develops liver metastases after adjuvant docetaxel/carboplatin/trastuzumab — Laurie Matt-Amaral, MD, MPH (15:30) Case: A woman in her late 80s with weakly ER-po...

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics: Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00) Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26) Emerging data with novel agents and strategies for th...

Featuring an interview with Prof Sia Daneshmand, including the following topics: Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00) Alternative induction regimens when BCG is not available (4:06) Treatment options for patients with BCG-refractory disease (8:46) Role of immunotherapy in treating NMIBC (13:58) Role of cystectomy in treating N...

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, including the following topics: Prologue: A vision for the future (0:00) Classification and prognosis of myelodysplastic syndromes (MDS) (23:34) Current management of lower-risk MDS (25:57) Current management of higher-risk MDS (38:16) MDS-Acute Myeloid Leukemia continuum and overlap: Venetoclax and other target...

Featuring perspectives from Dr Carl Gay, including the following topics: Introduction: Journal Club with Carl M Gay, MD, PhD (0:00) Case: A woman in her early 60s with extensive-stage small cell lung cancer (ES-SCLC) and a small residual lung mass after carboplatin/etoposide/atezolizumab — Kapisthalam (KS) Kumar, MD (19:15) Case: A woman and heavy smoker in her early 70s who develops widespread ES...

Featuring perspectives from Dr Stephanie Lheureux, including the following topics: Prologue: Seminars in Cancer Biology (0:00) Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54) Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33) Cas...

Featuring perspectives from Dr Robert Haddad, including the following topics: ESMO 2022 (0:00) Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39) Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21) Case...

Featuring perspectives from Dr Benjamin Levy, including the following topics: Disease biology of and therapeutic strategies for small cell lung cancer (SCLC) (0:00) Current and future management of limited-stage SCLC (3:32) Case: A man in his mid 70s with newly diagnosed SCLC and isolated brain metastases (5:51) Novel therapies for SCLC (21:51) Future directions for lurbinectedin in the treatment...

Featuring a slide presentation and related discussion from Dr Benjamin Levy, including the following topics: Immune checkpoint inhibitors for treatment-naïve extensive-stage small cell lung cancer (ES-SCLC) (0:00) Evaluating the role of lurbinectedin in therapy for SCLC (9:32) Impact of trilaciclib on myelosuppression in patients with ES-SCLC (19:08) Novel treatment strategies for patients with SC...

Featuring an interview with Dr Michael Birrer, including the following topics: Prologue (0:00) Multidisciplinary Management of Endometrial Cancer in Copenhagen, Denmark; Boston, Massachusetts and Little Rock, Arkansas (6:17) Subtypes of Endometrial Cancer (12:51) Treatment for Microsatellite Instability-High Endometrial Cancer (16:27) Microsatellite-Stable Endometrial Cancer (37:26) Future Directi...

Featuring a slide presentation and related discussion from Dr Amrita Krishnan, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with...

Featuring an interview with Dr Amrita Krishnan, including the following topics: Case: A woman in her early 60s who presents with renal failure and receives CyBorD for multiple myeloma (MM) (0:00) Dyspnea associated with carfilzomib; ocular toxicity with belantamab mafodotin (6:26) Efficacy, tolerability and sequencing of belantamab mafodotin for MM; myths and misperceptions (10:33) Case: A man in...

Featuring a slide presentation and related discussion from Dr Heather Wakelee, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with...

Featuring an interview with Dr Heather Wakelee, including the following topics: Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00) Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15) Activity of immunotherapy in patients whose tumors are EGFR mutate...

Featuring perspectives from Dr Richard Penson, including the following topics: Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00) Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28) Case:...

Featuring perspectives from Dr Mark Pegram, including the following topics: Introduction: Journal Club with Dr Pegram (0:00) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35) Case: A woman in her early 60s with a 1.8-cm tr...

Featuring perspectives from Dr Lecia Sequist, including the following topics: Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26) Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an "es...

Featuring a slide presentation and related discussion from Dr Stephen Ansell, including the following topics: Recent updates in the first-line management of advanced classical Hodgkin lymphoma (0:00) Emerging data with immune checkpoint inhibitors when combined with current treatment strategies (4:40) Current and future management of early-stage disease (9:53) Treatment options for patients with r...

Featuring perspectives from Dr Stephen Ansell, including the following topics: Evolution of first-line management of advanced Hodgkin lymphoma (HL) (0:00) Transplant strategies and outcomes for patients with relapsed/refractory HL (4:20) Chemoimmunotherapy options for patients with HL (8:06) Current and future management of limited-stage disease (11:52) Addition of antibody-drug conjugates to HL t...

Featuring a slide presentation and related discussion from Dr Charles Powell, including the following topics: Pathophysiology and clinical features of interstitial lung disease (ILD) associated with anticancer therapies (0:00) Anticancer therapies linked to the development of ILD (5:28) Patterns of ILD presentation and optimal evaluation of suspected ILD; treatment guidelines based on grade of sev...